Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

3.35USD
28 Apr 2017
Change (% chg)

$0.30 (+9.84%)
Prev Close
$3.05
Open
$3.20
Day's High
$3.75
Day's Low
$3.10
Volume
209,169
Avg. Vol
38,719
52-wk High
$5.59
52-wk Low
$2.35

AEZS.OQ

Chart for AEZS.OQ

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $45.51
Shares Outstanding(Mil.): 13.80
Dividend: --
Yield (%): --

Financials

  AEZS.OQ Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -2.39 -- --
ROI: -68.83 -0.42 13.25
ROE: -179.39 5.87 14.41

BRIEF-Aeterna Zentaris intends to file NDA with respect to Macrilen in Q3

* Aeterna Zentaris intends to file NDA with respect to Macrilen™ in third quarter of 2017 Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln

* Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing Source text (http://bit.ly/2mMXM6t) Further company coverage:

Mar 21 2017

BRIEF-Aeterna Zentaris qtrly loss per share $0.71

* Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results

Mar 15 2017

BRIEF-Aeterna Zentaris announces EMA pediatric committee agreement

* Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM)

Mar 07 2017

More From Around the Web

Earnings vs. Estimates